Medigene AG (0QGJ.L)

1,4800 -0,0200 (-1,33%) Al cierre: 08:02AM BST

Medigene AG

Lochhamer Strasse 11
Planegg/Martinsried
Munich 82152
Germany
49 89 2000 330
https://www.medigene.com

Sector(es): 
Sector: 
Empleados a tiempo completo: 76

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Selwyn Ho MB BS, MBBS	CEO & Member of Executive Management Board	384,47k	N/A	1971
Dr. Dolores J. Schendel	Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development	600k	N/A	N/A
Dr. Ernst-Ludwig Winnacker	Co-Founder & Chairman Scientific Advisory Board	20k	N/A	1941
Dr. Birger Kohlert	Chief Financial Officer	N/A	N/A	N/A
Pamela Keck	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Kirsty Crame M.D.	VP and Head of Clinical Research & Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Gobierno corporativo

El ISS Governance QualityScore de Medigene AG, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.